### Mucormycosis co-infection in COVID-19 patients: An update

Abdullah S. Alkhamiss, Ahmed A. Ahmed, Zafar Rasheed, Ruqaih Alghasham, Ali Shariq, Thamir Alsaeed, Sami A. Althwab, Suliman Alsagaby, Abdullah S. M. Aljohani, Fahad A. Alhumaydhi, Sharifa K. Alduraibi, Alaa K. Alduraibi, Homaidan T. Alhomaidan, Khaled S. Allemailem, Raya A. Alharbi, Samar A. Alamro, Arwa M. Alqusayer, Sahim A. Alharbi, Thekra A. Alharby, Mona S. Almujaydil, Ayman M. Mousa, Sultan A. Alghaniam, Abdulrhman A. Alghunaim, Rana Alghamdi, Nelson Fernández, Waleed Al Abdulmonem*

**Abstract:** Mucormycosis (MCM) is a rare fungal disorder that has recently been increased in parallel with novel infection in COVID-19 patients.

* Corresponding author: Waleed Al Abdulmonem, Department of Pathology, College of Medicine, Qassim University, Buraidah, Saudi Arabia, e-mail: dr.waleedmonem@qumed.edu.sa

**ORCID:** Waleed Al Abdulmonem 0000-0003-2984-9262

**https://doi.org/10.1515/biol-2022-0085**

**Open Access. © 2022 Abdullah S. Alkhamiss et al., published by De Gruyter.**

**License:** This work is licensed under the Creative Commons Attribution 4.0 International License.
COVID-19 infection. MCM with COVID-19 is extremely lethal, particularly in immunocompromised individuals. The collection of available scientific information helps in the management of this co-infection, but still, the main question on COVID-19, whether it is occasional, participatory, concurrent, or coincidental needs to be addressed. Several case reports of these co-infections have been explained as causal associations, but the direct contribution in immunocompromised individuals remains to be explored completely. This review aims to provide an update that serves as a guide for the diagnosis and treatment of MCM patients’ co-infection with COVID-19. The initial report has suggested that COVID-19 patients might be susceptible to developing invasive fungal infections by different species, including MCM as a co-infection. In spite of this, co-infection has been explored only in severe cases with common triangles: diabetes, diabetes ketoacidosis, and corticosteroids. Pathogenic mechanisms in the aggressiveness of MCM infection involves the reduction of phagocytic activity, attainable quantities of ferritin attributed with transferrin in diabetic ketoacidosis, and fungal heme oxygenase, which enhances iron absorption for its metabolism. Therefore, severe COVID-19 cases are associated with increased risk factors of invasive fungal co-infections. In addition, COVID-19 infection leads to reduction in cluster of differentiation, especially CD4+ and CD8+ T cell counts, which may be highly implicated in fungal co-infections. Thus, the progress in MCM management is dependent on a different strategy, including reduction or stopping of implicit predisposing factors, early intake of active antifungal drugs at appropriate doses, and complete elimination via surgical debridement of infected tissues.

**Keywords:** mucormycosis, immunocompromise, COVID-19, rhino-orbito-cerebral, pulmonary, diabetes: diabetes ketoacidosis, corticosteroids

# 1 Introduction

Mucormycosis (MCM) is described as a rare invasive fungal infection with high morbidity and mortality. Order Mucorales belong to the class Mucormycetes, subsequently to the subphylum Mucoromycotina [1]. It is associated with immunocompromised patients. However, several immunocompromised with various conditions including those with uncontrolled diabetes mellitus (DM), diabetic ketoacidosis, open wound following trauma, prolonged neutropenia, HIV or AIDS infection, iron overload or hemochromatosis, malignancies, corticosteroid therapy, organ transplant, and severe burns predispose this infection [2]. Although Mucorales belongs to nonpathologic fungus, the prevalence in immunocompetent individuals is a result of the existence of an intact immunity through neutrophils, which eliminate their spores [2,3]. Recently, severe COVID-19 infection was added as a co-factor that might cause a significant and sustained lymphopenia, leading to developing opportunistic infections, either bacterial or fungal. The first case was reported with COVID-19, which developed pulmonary cavitary lesions due to Mucorales fungi co-infection with harmful complications [3]. In fact, Mucorales fungi can invade blood vessels, which causes ischemic necrosis, and can potentially invades various systems such as the lung, central nervous system (CNS), nose, sinuses, skin, orbit, jaw bones, joints, heart, and kidney and can be classified into the following forms: pulmonary, rhino-cerebral, sino-nasal, cutaneous, oral mycosis, gastrointestinal, and disseminated [4]. This review article aimed to update the MCM information involving fungus classification, epidemiology, etiology, diagnostic tools, clinical settings, and treatment recommendations for invasive mycosis, which were found via the available original articles, original case reports, or published case series. Thus, this effort benefits to analyze and understand MCM via the available literature.

## 1.1 What is MCM?

MCM, previously known as zygomycosis, is the third most common invasive fungal infection after candidiasis and aspergillosis [2]. It is caused by mucoralean fungi (order Mucorales) [5]. Regarding a systematic position, the Mucorales order is considered more famous than the other zygomycotic fungi orders (Entomophthorales and Mortierellales) [6]. Order Mucorales belonging to class Phycomycetes consequently to subphylum Mucoromycotina, thus phylum Mucoromycotina (Zygomycota) [7]. Mucorales containing the family Mucoraceae, which are classified into genus (species) *Lichterman* (formerly *Absidia*) (*L. corymbifera*), *Apophysomyces* (*A. elegans*), *Mucor* (*circinelloides*, *hiemalis*, *racemosus*, *ramossimius*, *rouxianus*), *Rhizomucor* (*R. pusillus*, *mishear*), *Rhizopus* (*R. arrhizus*, *microsporus*, *schipperae*, *stolonifer*) (Figure 1) [8,9]. However, the order Entomophthorales contains two genera, Conidiobolus and Basidiobolus, which have been linked to human infections known as entomophthoromycosis. Mucorales are known to play a critical role in the development of MCM. In the last decade, according to molecular phylogenetic studies, the taxonomy of Mucorales has been modified widely and classified into 55 genera involving 261 species [10,11]. Thirty-eight species only have occasionally been implicated in MCM. But most of
MCM infection (about 70–80%) is attributed to *Mucor rouxii*, *L. corymbifera*, *R. pussillus*, and *R. arrhizus* (formerly *R. oryzae*) [1,12–14] (Table 1).

1.2 Major epidemiological and clinical manifestations of MCM infection in patients with COVID-19

Currently, 213 cases have been confirmed as COVID-19–associated mucormycosis (CAM) in many countries like India (129 cases, 59.7%), followed by Egypt (44 cases, 20.37%), Turkey (12 cases, 5.6%), the United States (9 cases, 4.16%), Iran (4 cases, 1.8%), the Netherlands (4 cases, 1.8%), France (3 cases, 1.3%), Brazil (1 case, 0.4%), the UK (2 cases, 0.9%), Italy (1 case, 0.4%), Mexico (1 case, 0.4%), Spain (2 cases, 0.9%), and Austria (1 case, 0.4%). The data are presented in Table 2 and summarized in Table 3. The most common isolated Mucorales included *Rhizopus* spp., *Mucor* spp., *Lichtheimia*, and *Aspergillus* spp. Of note, most of them have rhino-orbito-cerebral MCM (100 cases, 45.3%), followed by rhino-orbital MCM (68 cases, 30.5%). Pulmonary MCM was observed in 24 cases (10.8%). However,

### Table 1: Update synonyms of medically important Mucorales species regarding to recent taxonomy [21]

| Current nomenclature                  | Former names/synonyms                                                                 |
|---------------------------------------|--------------------------------------------------------------------------------------|
| *Lichtheimia ramosa*                  | Absidia ramosa, Mycocladus ramosus                                                  |
| *Lichtheimia corymbifera*             | Absidia corymbifera, Mycocladus corymbifera                                         |
| *Lichtheimia ornata*                  | Absidia ornata                                                                       |
| *Mucor cinclnelloides*                | Rhizomucor regularior, Rhizomucor variabilis                                        |
| *Mucor archlaengiktus*                | Mucor ellipsoideus, Mucor cinclnelloides                                           |
| *Mucor griseocyanus*                  | Mucor cinclnelloides                                                                 |
| *Mucor janssenii*                     | Mucor cinclnelloides                                                                 |
| *Mucor irregularis*                   | Rhizomucor variabilis                                                                 |
| *Mucor lusitanicus*                   | Mucor cinclnelloides                                                                 |
| *Rhizopus microsporus*                | Rhizopus azygosporus, Rhizopus chinensis, Rhizopus oligosporus,                    |
|                                       | Rhizopus rhizopodiformis, Rhizopus tuberosus                                        |
| *Rhizopus arrhizus*                   | Rhizopus oryzae                                                                       |
| Number of cases | Country | Clinical presentation of MCM | Site of infection | Species | Underlying host risk factor | Diagnostics | Antifungal therapy | Outcome | Reference |
|-----------------|---------|-----------------------------|-------------------|---------|----------------------------|-------------|-------------------|---------|-----------|
| 1               | USA     | Rhino-orbital               | Nasal sinus, orbit | NA      | DKA, HTN, asthma           | CT scan, histopathological | Liposomal Amphotericin B | Improved | [94]      |
| 2               | USA     | Rhino-orbital-cerebral     | Nasal sinus, orbit, CNS | NA      | DM, DKA, received corticosteroids | CT scan, histopathological, and microbiological | Not mentioned | Died (n = 1), unchanged (n = 1) | [93]      |
| 1               | UK      | Pulmonary                   | Lung               | NA      | HTN, obesity, hypothyroidism | Q PCR, histochemical and immunohistochemistry examination | Not mentioned | Died (n = 2), improved (n = 4) | Autopsy report [109] |
| 1               | USA     | Pulmonary                   | Lung               | *Rhizopus* species | Not mentioned | CT scan, cultural examination | Amphotericin B | Died | [95]      |
| 11              | India   | Rhino-orbital-cerebral     | Nasal sinus, orbit CNS majority | NA      | DM, HTN | Cultural and histopathological examination | Amphotericin B | Died (n = 2), LFU (n = 5), improved (n = 4) | [106]     |
| 1               | USA     | Rhino-orbital               | Nasal sinus, orbit | NA      | DM, DKA | Histopathological and microbiological examination | Echinocandins and amphotericin B | Improved | [97]      |
| 10              | India   | Rhino-orbital-cerebral     | Nasal sinus, orbit = CNS | *Rhizopus* spp. | DM, DKT, received corticosteroid | Radiological and microbiological examination | Liposomal amphotericin B, dexamethasone | Died (n = 4), improved (n = 2), survived (n = 4) | [104]     |
| 1               | USA     | Pulmonary                   | Lung               | *Rhizopus* oxysporus | Non mentioned | CT scan, histopathological Microbiological examination | Echinocandins and amphotericin B | Died | [99]      |
| 1               | USA     | Cutaneous                   | Skin               | *Rhizopus* microsporus |DM, heart transplantation, received corticosteroid | CT scan cultural and microbiological examination | Amphotericin B, Caspofungin | Died | [100]     |
| 23              | India   | Rhino-orbital-cerebral     | All-nasal sinus 10 = orbit 2 = CNS | NA      |DM HTN received corticosteroid | MRI, CT scan | Surgical debridement, amphotericin B | LFU (n = 2), survived (n = 21) | [108]     |
| 1               | Italy   | Pulmonary                   | Nasal sinus lung   | *Rhizopus* spp. | HTN | CT scan examination and histopathological examination | Amphotericin B | Died | [3]       |
| Number of cases | Country | Clinical presentation of MCM | Site of infection | Species | Underlying host risk factor | Diagnostics | Antifungal therapy | Outcome | Reference |
|-----------------|---------|-------------------------------|-------------------|---------|----------------------------|-------------|--------------------|---------|-----------|
| 1               | France  | Pulmonary                     | Lung              | Rhizopus microsporus | Lymphoma, hematopoietic stem cell transplantation | Fungal qPCR, CT scan | Liposomal amphotericin B | Died    | [114]     |
| 1               | India   | Sino-orbital                  | Nasal sinus, orbit | Rhizopus oryzae | Received corticosteroid | MRI, histopathological examination | Surgery debridement, fluconazole, amphotericin B | Improved | [112]     |
| 2               | Iran    | Rhino-orbito-cerebral         | 2 = nasal sinus 2 = orbit 1 = CNS | NA | 1 = DM, received corticosteroid | Histopathological CT scan | Endoscopic sinus debridement, amphotericin B | Died (n = 1), improved (n = 1) | [116]     |
| 6               | India   | Rhino-orbital-cerebral        | All = nasal sinus, All = orbit 5 = CNS | NA | DM, received corticosteroid | Cultural, and histopathological examination, MRI | Liposomal amphotericin B, posaconazole, surgical debridement | Improved | [103]     |
| 1               | Mexico  | Rhino-orbital                 | Nasal sinus, orbit | NA | DKA | Cultural examination, CT scan | Surgery debridement | Died         | [118]     |
| 1               | Austria | Pulmonary                     | Lung              | Rhizopus microsporus | Leukemia | CT scan examination and histopathological examination | Voriconazole | Died         | [119]     |
| 1               | India   | Rhino-orbital                 | Nasal sinus, orbit | NA | Not mentioned | MRI CT scan | Vancomycin, amphotericin B | Died | [110]     |
| 1               | India   | Pulmonary                     | Lung              | Rhizopus microsporus | DM, HTN | CT scan, microbiological examination | Amphotericin B | Improved | [109]     |
| 1               | Iran    | Rhino-orbital                 | Nasal sinus, orbit | NA | NOD, received corticosteroid | Histopathological CT scan | Unknown | Improved | [115]     |
| 1               | India   | Rhino-sinuses                 | Nasal sinus, orbit | NA | DM, | MRI, histopathological examination | Endoscopic sinus surgery, amphotericin B | Improved | [113]     |
| 1               | India   | Rhino-orbital–cerebral        | Nasal sinus, orbit, CNS | NA | DM, NDD | CT scan, MRI, histopathological examination | Amphotericin B | Improved | [102]     |
| 1               | USA     | Pulmonary                     | Lung              | Rhizopus arrhizus | DM, received corticosteroid | CT scan, histopathological, and microbiological examination | Not mentioned | Improved | [98]      |
| 10              | India   | Rhino-orbital                 | All = nasal sinus 2 = orbit 1- bone | NA | DM | Histopathological examination, CT scan, and MRI | Amphotericin B | Died (n = 1), survived (n = 3), improved (n = 5), LFU (n = 1) | [105]     |

(Continued)
| Number of cases | Country | Clinical presentation of MCM | Site of infection | Species | Underlying host risk factor | Diagnostics | Antifungal therapy | Outcome | Reference |
|----------------|---------|-----------------------------|-------------------|---------|-----------------------------|-------------|-------------------|---------|-----------|
| 11             | India   | Rhino-orbital-cerebral      | Nasal sinus, orbit, CNS majority | NA      | DM, HTN                     | Cultural and histopathological examination, CT scan | Amphotericin B | Died (n = 2), LFU (n = 5), improved (n = 4) | [106]   |
| 1              | USA     | Rhino-orbital-cerebral      | Nasal sinus, CNS | Rhizopus species | DM, asthma, HTN, hyperlipidemia | CT scan, histopathological and microbiological examination | Endoscopic surgical debridement, vancomycin, cefepime, liposomal amphotericin B | Died | [96]     |
| 1              | Brazil  | Gastrointestinal            | Gastrointestinal | NA      | HTN                         | Esophagogastroduoden, CT scan, histopathological examination | Unknown | Died | [101]   |
| 1              | Turkey  | Rhino-orbital-cerebral      | Nasal sinus, orbit CNS | NA      | DKA. received corticosteroid | Cultural examination, CT scan | Surgery debridement, amphotericin B | Died | [117]   |
| 1              | Brazil  | Palatal ulcer               | Ulcerated, lesion with, coagulative, necrosis, hemorrhage, and abundant neutrophils | NA      | DM                          | Histopathological examination, cultural examination, CT scan | Surgery debridement, amphotericin B | Survived | [117]   |
| 1              | India   | Rhino-orbital               | Periorbital pain followed by sudden onset of vision loss in the left eye | NA      | DM                          | Histopathologic identification, cultural examination, CT scan | Surgery debridement, amphotericin B | Survived | [118]   |
| 31             | India   | Rhino-orbital               | Orbital cellulitis, ophthalmoplegia | NA      | DM received corticosteroid (n = 19) | Cultural examination, CT scan | Surgery debridement, amphotericin B | Survived (n = 28), died (n = 3) | [119]   |
| 1              | Iran    | Rhino-orbital               | Variable          | NA      | DM received corticosteroid | Histopathological examination | Combined antifungal, surgery debridement | Died | [120]   |
| 1              | India   | Gastrointestinal            | Abdominal pain, nausea, vomiting | NA      | NA                          | Histopathological examination, cultural examination, CT scan | Liposomal amphotericin B | Improved | [121]   |
| 10             | India   | Rhino-orbital               | Headache and facial pain | NA      | Received corticosteroid   | Histopathological examination, cultural examination, CT scan | Amphotericin B, deoxycholate, and isavuconazole | Died (n = 1), survived (n = 9) | [122]   |

(Continued)
| Number of cases | Country | Clinical presentation of MCM | Site of infection | Species | Underlying host risk factor | Diagnostics | Antifungal therapy | Outcome | Reference |
|----------------|---------|-----------------------------|------------------|---------|----------------------------|-------------|-------------------|---------|-----------|
| 6              | India   | Paranasal sinusitis         | Headache and facial pain | NA      | DM                         | Histopathological examination, cultural examination, CT scan | Surgery debridement, amphotericin B | Improved (n = 6) | [123]    |
| 1              | India   | Abdominal                   | Abdominal pain, nausea, vomiting | NA      | DM                         | Radiographic and histopathology in selected patients | Surgery debridement, amphotericin B | Died     | [124]    |
| 1              | India   | Rhino-orbital               | Acute loss of vision | NA      | NA                         | Histopathological examination, Culture from the necrotic tissue | Surgery debridement, amphotericin B | Recovered | [125]    |
| 2              | Spain   | Abdominal (n = 1), musculoskeletal (n = 2) | Abdominal and facial pain, | NA      | DM, kidney transplantation (n = 1), HTN, steroid taken (n = 2) | Cultural examination, CT scan | Surgery debridement, amphotericin B (n = 2), and initially isavuconazole, and subsequently posaconazole (n = 1) | Died (n = 1), survived (n = 1) | [126]    |
| 11             | Turkey  | Rhino-orbital (n = 8), Rhino-orbito-cerebral (n = 3) | 8 = nasal sinus, 8 = orbit 3 = CNS | NA      | DM (n = 8), HTN (n = 7), renal failure (n = 5) | Cultural examination, CT scan | Radical debridement, amphotericin B | Died (n = 7), survived (n = 4) | [127]    |
| 2              | India   | Maxillo-facial              | Facial pain       | NA      | DM (n = 1), HTN (n = 2) | Maxillary biopsy, cultural examination, CT scan | Radical debridement, amphotericin B | Survived (n = 2) | [128]    |
| 8              | Egypt   | Pulmonary                   | Respiratory system, orbital cavities, ethmoidal and maxillary sinuses, nasal cavity, nasopharynx, carotid artery, hard palate, skin | Aspergillosis | DM (n = 6), chronic kidney disease (n = 2), hyperlipidemia (n = 2), HTN (n = 2), ischemic heart disease (n = 1), cerebral infarction (n = 1) | Radiographic and histopathology in selected patients | Amphotericin B, ambisome, itraconazole, surgical debridement, orbital enucleation, mechanical ventilation | Survived (n = 5), died (n = 3) | [129]    |
| 4              | Netherlands | Pulmonary, rhino-orbital, rhino-sinuses | Respiratory failure, Acute-onset kidney failure, extensive sinusitis | Rhizopus microsporus, Lichtheimia ramosa, A. fumigatus, R. arrhizus | DM (n = 2), chronic lymphocytic lymphoma (n = 1), obesity (n = 1) | Radiographic and culture | Tocilizumab, dexamethasone, prednisone, amphotericin B, posaconazole, voriconazole, isavuconazole, surgical debridement, | Died (n = 3), survived (n = 1) | [130]    |
| Number of cases | Country | Clinical presentation of MCM | Site of infection | Species | Underlying host risk factor | Diagnostics | Antifungal therapy | Outcome | Reference |
|-----------------|---------|-----------------------------|------------------|---------|-----------------------------|-------------|-------------------|---------|-----------|
|                 |         |                             |                  |         |                             |             |                   |         | [131]     |
| 1               | UK      | Pulmonary, heart, hilar nodes, brain, pharynx, nasal mucosa, trachea | Acute anterior cerebral artery, pneumonitis | Aspergillosis | Hypothyroidism, steatohepatitis, thrombo-embolic disease | PCR, radiographic and culture | interferon-γ, mechanical ventilation | Died | [131]     |
|                 |         |                             |                  |         |                             |             | aspirin, LMW-heparin, hydroxychloroquine, azithromycin, meropenem, teicoplanin, argatroban, noradrenaline, vasopressin, gentamicin, tracheostomy, bronchoalveolar lavage | |           |
| 36              | Egypt   | Rhino-orbital–cerebral (n = 29), sino-orbital (n = 7) | Facial pain facial numbness, ophthalmoplegia, and visual loss | *Mucor* and *Aspergillus* species | DM (n = 10), HTN (n = 6), leukemia (n = 1), pancreatic cancer (n = 1), CKD (n = 3), asthma (n = 3), cardiac (n = 1), hypothyroidism (n = 1), systemic lupus erythematosus (n = 2) | MRI, histopathological diagnosis | Amphotericin B, voriconazole, posaconazole, surgical debridement, mechanical ventilation | Died (n = 13), survived (n = 23) | [132]     |
| 2               | France  | Pulmonary                    |                  | *Aspergillus* | Obesity (n = 2), kidney transplantation (n = 1), HTN (n = 1), dyslipidemia (n = 1) | MRI, histopathological diagnosis | One had no specific antifungal or COVID-19 treatments (died later). One received no specific COVID-19 therapies, but voriconazole, amphotericin B, caspofungin, and isavuconazole for fungal infections (alive) | Died (n = 1), survived (n = 1) | [133]     |

Q PCR, quantitative polymerase chain reaction; CT scan, computed tomography; MRI, magnetic resonance imaging; DM, diabetes mellitus; HTN, hypertension; CNS, central nervous system; GIT, gastro-intestinal tract; DKA, diabetic ketoacidosis; NOD, new-onset; NA, not available; LFU, lost to follow-up; LAMA, left against medical advice.
### 1.3 Etiology

When healthy individuals with immunocompetent inhale or ingest the fungal spores or lacerations of the mucosa via the nasal passage or oral cavity, they will not be implicated in immediate or potential harm as the phagocytic response will limit its prevalence. In contrast to the individual with immunocompromised and low polymorphonuclear leukocytes, the fungi become pathogenic when individuals inhale by the fungal spores through lacerations of the mucosa in the oral or nasal cavity, may develop hyphae, and reach the paranasal sinuses. Subsequently, the disease can develop and diffuse to the cavernous sinus, the orbits, and the brain. It can also invade the arterial lamina and lead to tissue necrosis or thromboembolisms and infarctions of involved tissues. Then, the patient might suffer from orbital cellulitis, orbital apex syndrome, cerebritis or brain abscess, and a high mortality rate [15]. Mucorales and Entomophthorales orders are the most common etiological agents of MCM in humans. Several co-factors have been reported for a steady increase in MCM risk, such as:

1. Immunosuppression following solid organ, stem cells, and bone marrow transplants [16].
2. Severe neutropenia consequence of aggressive chemotherapy for hematological and solid malignancies since neutrophils are essential for phagocytosis of the fungus [17].
3. Rate of breakthrough invasive fungal infections is estimated between 4 and 10% of patients who are taking antifungal prophylaxis or treatment [18,19].

Uncontrolled DM and insufficient healthcare access can lead to an increase in MCM risk factors and hyperglycemia, which contributes to impaired neutrophil function and may cause MCM [20]. Therefore, DM is the most commonly known risk factor for MCM, especially during ketoacidosis. This is because ketones facilitate the fungi to utilize and produce ketoreductase, which facilitates its growth. In addition, hyperglycemia with ketoacidosis is also directly associated with the risk of MCM in different ways: (a) incidence of iron imprisonment because of hyperglycration of iron, which reduces the host protective system; (b) enabling tissue breakthrough by expressing the glucose-regulated protein 78 (GRP78) of cell receptor, which binds to Mucorales fungal species through the direct effect of hyperglycemia and indirectly by raising free iron levels; (c) deteriorating phagocytic functions and diminution the efficiency of chemotaxis; and (d) enhancing fungal existence via iron dissociation from

| Table 3: Summary of mucormycosis infection in COVID-19 patients |
|--------------------------------------------------------------------------------------------------|
| **Countries**                                                                                   |
| India                                                                                           | 129 (59.7) |
| Egypt                                                                                           | 44 (20.37) |
| Turkey                                                                                          | 12 (5.6)   |
| USA                                                                                             | 9 (4.16)   |
| Iran                                                                                            | 4 (1.8)    |
| Netherland                                                                                      | 4 (1.8)    |
| France                                                                                          | 3 (1.3)    |
| Brazil                                                                                         | 1 (0.4)    |
| UK                                                                                              | 2 (0.9)    |
| Italy                                                                                           | 1 (0.4)    |
| Mexico                                                                                          | 1 (0.4)    |
| Spain                                                                                           | 2 (0.9)    |
| Austria                                                                                        | 1 (0.4)    |
| Clinical manifestations                                                                        |
| Rhino-orbito-cerebral                                                                         | 100 (45.3) |
| Rhino-orbital                                                                                   | 68 (30.5)  |
| Pulmonary                                                                                       | 24 (10.8)  |
| Sino-orbital                                                                                   | 14 (6.3)   |
| Gastrointestinal                                                                               | 8 (4.0)    |
| Others                                                                                          | 7 (3.1)    |
| Risk factors                                                                                   |
| Diabetes mellitus                                                                               | 93 (42.7)  |
| Diabetes ketoacidosis                                                                           | 18 (8)     |
| Hypertension                                                                                   | 96 (42.7)  |
| Another comorbidity                                                                             | 8 (3.6)    |
| Glucocorticoid’s intake                                                                         | 67 (31.0)  |
| Amphotericin B                                                                                  | Major      |
| Surgical debridement                                                                           | Major      |
| Outcomes                                                                                        |
| Deceased                                                                                        | 57 (27.3)  |
| Alive                                                                                           | 143 (66.6) |
| Lost follow-up                                                                                  | 13 (6.0)   |
breakthrough proteins [21]. GRP78 was involved within the cell receptor of endothelial vascular tissue [22].

1.4 Environmental factors and distribution of MCM

From an environmental perspective, these fungi are distributed in the soil, compost, animal feces, and decaying materials. In France, the analysis of collected soil samples from different geographical zones demonstrated that the most common species of Mucoralean fungi are *Mucor circinelloides*, *Rhizopus arrhizus* (synonym: *Rhizopus oryzae*), *Lichtheimia corymbifera*, *Rhizopus microsporus*, and *Cunninghamella bertholletiae* [8,9]. In comparison, a novel species have been discovered in Mexico (*Apophysomyces mexicanus*) [23]. Thus, the most common species of Mucorales found in the European countries are *Rhizopus* spp. (34%), *Mucor* spp. (19%), and *Lichtheimia* spp. (19%) [24], whereas in the United States, *Rhizopus* species were followed by *Mucor* species (19%), *Rhizomucor* species (7%), *Cunninghamella* species (9%), and *Lichtheimia* species (formerly *Absidia* species, 3%) [5]. Of note, MCM incidence among geographical regions is possibly due to the different natural habitats [24]. Conversely, the peak of MCM incidence has been investigated from September to November (autumn season) in some Middle East countries [8,25,26], while in European countries, most incidences are recorded in autumn and winter [27]. As well as in tropical and subtropical zones, the distribution of MCM was higher in autumn [28], suggesting that climate conditions may play a critical role in the prevalence of MCM and might have contributed to increasing airborne spore concentrations in autumn, whereas the fewer concentrations occur in summer. MCM incidence varies considerably from zone to zone regarding the susceptibility of co-factors. Several studies from Europe [24,29,30] reported that hematological malignancy was the most co-factor of infection, while in India [27,31,32], Iran [33], Mexico [31], Middle East, and North Africa [34], it was DM. Conversely, several studies have demonstrated that the underlying disease is associated with the site of infection [13,28,35]. However, hematological malignancies and neutropenia are correlated with pulmonary MCM, whereas DM is correlated with sinusitis and rhino-cerebral disease, while trauma usually leads to cutaneous MCM. DM and ketoacidosis DM is contributing to underlying disease in cases with MCM globally [13,35].

1.5 Diagnosis

Fast treatment of MCM disease is considered a big challenge. Therefore, the accuracy of diagnosis is very important for helping the treatment and reducing the high mortality (85%, concerned with late or incorrect diagnosis) [2]. Continuous development and discovering an accurate diagnosis are still essential because of the indirect clinical markers/symptoms for confirming MCM. Update of studies is required to understand the epidemiology and diagnosis of this disease among various regions worldwide. In spite of this, multiple studies reported the difficulty in establishing a rapid diagnosis [36]. The first step in the diagnosis begins with suspicion of the occurrence of MCM infection, especially the candidate diseases as co-factors. Hence, progress in diagnosis has affected the increasing reports on invasive MCM in susceptible patients like those with diabetic ketoacidosis secondary to uncontrolled DM, HMs, solid organ transplant, chronic respiratory diseases, and corticosteroid therapy [37]. Although, a conventional clinical path for diagnosis lacks specificity and sensitivity. It is still a basic requirement for the initial diagnosis of MCM when a high indicator of suspicion, via estimate of host factors and fast evaluation of clinical appearances. For example, the initial investigation of gastric MCM by endoscopic examination usually reveals an ulcer with necrosis, ultimately presenting an adherent, thick, green exudate [38]. Histopathology and culture are the fundamentals of diagnosis [13,39]. Prompt microscopy examination of clinical biopsy specimens is carried out, perfectly using optical brighteners such as Blankophor and Calcofluor [40–42]. White in clinical specimens gives a fast visualization of the characteristic fungal hyphae of MCM, in this case requiring a fluorescent microscope [2,43]. Also, in the case of diplopia in diabetic patients, pleuritic pain may be an indicator of this infection, and it is essential to obtain a specimen for traditional examination by histopathological and microbiological examinations or by advanced molecular techniques. The markers and symptoms that involve diplopia are cranial nerve palsy, proptosis, sinus pain, orbital apex syndrome, periorbital swelling, and ulcers of the palate [42]. In addition, radiologically, various (≥10) nodules and pleural emissions can reveal the association with pulmonary MCM [44]. Other pathways are computerized tomography (CT) scans with high-resolution and magnetic resonance imaging (MRI), which indicate the existence of MCM [2,13,45]. When studying the CT features of COVID-19–associated pulmonary mucormycosis situations, it was discovered that consolidation and cavitation were the most
common computed tomography imaging findings (69%), probably because of delayed disease diagnosis [46]. According to another CT imaging study, almost all the patients (95.7%) displayed signs of pansinusitis. The infection spread beyond the paranasal sinuses was seen in 78.7% of cases, with orbital invasion 40.4% being the most prevalent [47]. On the contrary, MRI is useful for soft tissue imaging and determining the severity of disease [48]. Conversely, identifying different fungal species is important for the best epidemiological understanding of MCM and may be of significance for outbreak determinations. Mucorales fungi can be easily identified in culture. One study described the morphological features alone, and when distinguished by specialists in the fungal investigation, a high level of accuracy can be obtained. [49,50] However, identifying species is still difficult and may face failures in speciation, whereas immunohistochemistry using monoclonal antibodies against R. arrhizus can differentiate aspergilllosis from MCM (100% high sensitivity and 100% high specificity for MCM) [51,52]. Recently, a molecular diagnosis is required either for the identification or detection of MCM [53]. It involves conventional polymerase chain reaction (PCR), [54–56], restriction fragment length polymorphism (RFLP) [56,57], and DNA sequencing [2,58]. Indeed, several PCR-based techniques have been developed, such as nested PCR, real-time PCR [59,60] (quantitative PCR (qPCR)), nested PCR combined with RFLP [61], PCR coupled with electrospray ionization mass spectrometry [62], and PCR/high-resolution melt analysis [63]. All assays mentioned earlier can be applied for either the identification or the detection of Mucorales. Most of the molecular assays are ribosomal targets (18S, 28S, and internal transcribed spacer) or DNA targets (the high-affinity iron permease I gene FTRI or cytochrome b) [53,64–67]. Several studies have been performed by using either fresh tissue specimens or formalin-fixed paraffin-embedded [68–70], yet resulting in different performances. Recent tools directed at molecular assays from blood serum [68,71–73] have yielded promising clinical data with the advantage of early diagnosis in comparison with culture. Moreover, qPCR has been performed to identify circulating Mucor/Rhizopus, Lichtheimia, and Rhizomucor DNA in the serum [74]. However, some studies recommended that molecular diagnosis can be conducted in addition to conventional diagnosis tools [75].

### 1.6 COVID-19 and mucormycosis co-infections

Based on clinical manifestations, invasive MCM can be classified by the anatomic site affected into six main forms: pulmonary, rhino-orbital-cerebral, cutaneous, sinus, gastrointestinal, disseminated, and rare forms, such as endocarditis, osteomyelitis, peritonitis, and renal infection [76–78]. Any of Mucorales species can infect any of these sites. Fungal infection can invade these sites by the incorporation or implantation of the fungal spores through oral, nasal, and conjunctival mucosa (rhino-orbital-cerebral), by inhalation (pulmonary), or by the ingestion of contaminated food (gastrointestinal), as they rapidly colonize nutrients rich of glucose for its principal energy source [79]. Then the common ratio of invasive MCM was evaluated as follows: sinuses (39%), pulmonary (24%), and cutaneous (19%) [80]. Dissemination developed in 23% of this infection [81,82]. However, these values may be changeable depending on the incidence of another co-factor such as COVID-19. The first report has suggested that COVID-19 patients might be susceptible to developing invasive fungal infections by different species such as candidiasis, invasive aspergillosis, and pneumocystis jiroveci [83]. However, this report did not include MCM as a co-infection with the COVID-19 pandemic. Subsequently, the case report presented a patient with MCM without any conventional risk factor. The infection was confirmed after being diagnosed with COVID-19 and has been treated with broad-spectrum antibiotics and corticosteroids (which are critical factors for invasive fungal infection) [78,84]. Despite co-infection among patients with COVID-19 has been shown only in severe cases [82,85,86], superinfections in viral pneumonia remain unclear. The first reason is due to challenges confused by the conventional diagnosis of Mucorales. The second is due to the fact that many centers minimized direct testing of at-risk respiratory samples during the current COVID-19 pandemic to diminish exposure to the virus [87–90]. Subsequently, several reports confirmed increasing cases of MCM in different countries, particularly in India, after COVID-19. Of their findings of an even larger case series of MCM cases in COVID-19, about 80% of cases had DM and more than 75% of cases received a course of corticosteroids. Therefore, these findings indicated that the common triangle associated with COVID-19 and MCM co-infection are DM, diabetic ketoacidosis (DKA), and corticosteroids (Table 2) [3,89–113]. However, some finding in case of rhino-orbital MCM was associated with ketoacidosis DM and infection with severe acquired respiratory syndrome coronavirus 2 [134]. Song et al. have reported an algorithm for the early diagnosis and management of common invasive fungal infections such as MCM, aspergillosis, candidiasis, and cryptococcosis during the COVID-19 pandemic [135]. However, factors leading to increased incidence of opportunistic fungal infections during the COVID-19 pandemic may lead to immunosuppression due to high-dose corticosteroids in the
management of the pandemic, thus leading to immunosuppression [136]. Corticosteroid intake during COVID-19 infection often leads to uncontrolled diabetes and precipitation of ketoacidosis. Thus, acidosis (low pH) is considered a favorite media for *Mucor* spores to grow. In addition, corticosteroid intake also reduces the phagocytic activity of white blood cell (WBC) and causes deterioration of bronchoalveolar macrophages migration, ingestion, and phagolysosome fusion, leading to exposure risk of diabetic people to MCM [89]. Consequently, a report described one case with SARS-CoV-2 infection who developed a cavitary pulmonary MCM [137]. Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection might develop coronavirus disease (COVID-19), which can be associated with significant and sustained lymphopenia compromising the immune system, especially in the most severe cases [3,138–141]. Recent findings described that a significant decrease in lymphocyte count and an increase in neutrophil count together with an inflammatory storm occur more frequently in patients who developed severe COVID-19 and co-infections [141]. Pathogenic mechanisms in aggressive MCM involve reduced phagocytic activity, attainable quantities of ferritin attributed to the displacement of protons by transferrin in diabetic ketoacidosis, and fungal heme oxygenase, which enhances iron absorption for its metabolism. Therefore, severe COVID-19 cases with hemato-lymphohistioctysis syndrome are associated with the increasing risk factors of invasive fungal co-infections [90]. Clinically, cell counts exhibited that there was an increase in neutrophils and WBC count, but a decrease in lymphocytes progressively [3]. In addition, corticosteroid intake also reduces the phagocytic activity of WBC and causes deterioration of bronchoalveolar macrophages migration, ingestion, and phagolysosome fusion, leading to a diabetic people exposure risk to MCM. Conversely, the presence of free iron is an ideal co-factor for MCM. Hyperglycemia leads to glycosylation of transferrin and ferritin, and minimizing iron-binding leads to a raised ratio of free iron. Moreover, an increase in interleukin (IL)-6 among COVID-19 patients also causes an increase in free iron by elevating ferritin levels, and acidosis increases free iron by reducing the ability of transferrin to chelate iron [89]. In addition, COVID-19 infection drastically affects the immune system via hyperexpression of both proinflammatory (IL-1, IL-2, IL-6, and tumor necrosis factor (TNF-α)) and anti-inflammatory (IL-4, IL-10, and IL-17) cytokines [4,139] and hypoexpression of interferon (IFN)-γ. With an increase in neutrophiles, impaired lymphocyte-mediated immunity (Th1 and Th2) occurs. Subsequently, COVID-19 infection reduces the cluster of differentiation, especially CD4+ and CD8+ T cell counts, which may be highly implicated in fungal co-infections [141]. Critical cases, especially those admitted to intensive care units and those requiring longer hospital stays might be more prospective to evolve fungal co-infections [142]. Therefore, it is to be noted that severe Covid-19 susceptible to opportunistic fungal co-infections, especially MCM.

### 1.7 Molecular mechanism of mucormycosis in COVID-19 patients

The invasion of fungi usually starts by inhalation of spores during respiration (sometimes from ears), ingesting contaminated food, or invading through injuries/abrasion in the epidermis. Endothelialitis is the one factor of SARS-CoV-2 that might reveal the risk of MCM co-infection in COVID-19 patients. [143,144] Damage to endothelium promotes angio-invasion and prevalence of MCM. In addition, low pH, hyperglycemia, hyper-ferritin, and hyper-ketone due to COVID enhance an appropriate environmental condition for GRP78 of endothelial cells and fungal ligand spore coating homolog (CotH) protein. Molecular explanation between fungal CotH protein and nasal GRP78 enhances adherence in the early stage of infection (Figure 2). Then, the CotH surface proteins might act as invasion enzymes to cause the infection [145]. In the sequent step of infection, patients with the high levels of CotH and GRP78 lead to trapping of fungi inside sinus cavities (Figure 2) [146,147]. Then, fungal cells elongate into tube-like hyphal strands and disseminate into the sinuses, lungs, skin, soft tissues, and bloodstream, causing tissue and epithelium penetration (Figure 2). The second current pathway, corticosteroid intake, is the mainstay therapy in severe COVID-19 patients [148]. However, corticosteroid intake reduces the phagocytic capacity of WBCs, displaying patients’ fungal infections. In addition, new-onset corticosteroid-induced DM or exacerbated chronic DM with or without DKA might promote the replication of MCM. The COVID-19 itself launches a chain of events that might render patients prone to MCM infection. Thus, there are expected mechanisms through which SARS-CoV-2 infection might lead to MCM susceptibility. Dramatic elimination in the total number of T-cells involving both CD4+ and CD8+ groups in severe cases of COVID-19 causes significant lymphopenia successive an immunocompromised state and then susceptibility to MCM [4]. During severe COVID-19 infection, inflammatory cytokines such as IL-6, IL-2R, IL-10, and TNF-alpha elevate and lead to a term called “cytokine storm,” resulting in lymphopenia [4]. Consequently, cytokine storm raises iron levels and reduces its export. As a result, iron accumulates inside the cells. Iron overload causes tissue damage and
necrosis. In addition, free iron is ideal for growth and spreading MCM (Figure 2) [149,150]. Moreover, SARS-induced pneumonia results in atelectasis, which results in COVID-19-contributed silent hypoxia. Usually, the hypoxia-inducible factor 1 (HIF-1) stays inactive in normal conditions. During hypoxic conditions of COVID-19, the HIF-1α transcription factor subunit has a risky role in the expression of the COVID-19 receptor gene (ACE-2 gene), and hypoxia causes endothelium damage and upregulation of adaptive and innate immunocytes [151,152]. The overall effect of HIF-1 results in raised localized inflammation and tissue damage in COVID-19 patients. In addition, COVID-19 infection has also been demonstrated to impact ferritin metabolism. Therefore, several studies have reported hyperferritinemia syndrome post-COVID-19 infection. Thus, high free iron levels lead also to tissue damage via the production of reactive oxygen species (ROS) [150,153–156]. The overall potentials such as corticosteroid therapy, immunocompromised state, DM, DKA, hyperglycemia, hypoxia, cytokine storm, hyperferritinemia, neutropenia, metabolic dysfunction, and ROS make COVID-19–infected patient more susceptible to MCM. These main symptoms increased the body temperature, and altered osmolarity make an ideal environment for the growth and development of MCM (Figure 2).

### 1.8 Antifungal treatments

Progress in management and treatment of MCM is dependent on a different strategy, including reduction or stopping of implicit predisposing factors, early intake of active antifungal drugs at appropriate doses, complete elimination via surgical debridement of infected tissues, and administration of assistant therapies [57]. The therapy includes available antifungal medicines such as azithromycin, oseltamivir, ceftriaxone, amphotericin B (liposomal), ceftipeim, meropenem, linezolid, caspofungin, vancomycin, piperacillin, tazobactam, and oseltamivir. Intravenous amphotericin B (a lipid formulation) is the best and most common medicine for initial treatment, especially with
COVID-19 co-infection. Despite surgical operations and available antifungal drugs, the prognosis for recovery from MCM is poor [95,106] (Table 2). Kieliszek and Lipinski [157] suggested that the sodium selenite, but not selenate, possibly oxidizes viral thiol groups in the virus protein disulfide isomerase, coating it incapable to penetrate the host cell membrane. In this way, the sodium selenite inhibits invasion of viruses into the healthy cells and diminishes their infectivity [157]. Thus, this simple chemical compound is potentially applied to the recently infected COVID-19 patients all over the globe.

2 Conclusion

The increase in MCM worldwide due to co-factors, especially diabetes with or without ketoacidosis, leads to outbreaks of corticosteroid intake during the incidence of COVID-19 (increases in blood glucose lead to opportunistic fungal infection). Outbreaks of COVID-19 are accompanied by immunocompromised through hyperexpression of both proinflammatory (IL-1, IL-2, IL-6, and TNF-α) and anti-inflammatory (IL-4, IL-10, and IL-17) cytokines, and vice versa with IFN-γ. With an increase in neutrophils, impaired lymphocyte-mediated immunity (Th1 and Th2) occurs. Subsequently, COVID-19 infection leads to a reduction in the cluster of differentiation, especially CD4+ and CD8+ T cell counts, which may be highly implicated in fungal co-infections. Therefore, it is to be noted that severe COVID-19 susceptible to opportunistic fungal co-infections, especially MCM. Every effort should be made to progress in the management and treatment of MCM is dependent on a different strategy, including reduction or stopping of implicit predisposing factors, early intake of active antifungal medicines. Corticosteroids were used only in cases co-infected with COVID-19 to reduce the load of mortal MCM.

Acknowledgments: The researchers would like to thank the Deanship of Scientific Research, Qassim University, for funding the publication of this project.

Funding information: Authors received funding from the Qassim University.

Author contributions: A.A.A., A.A.A., A.S., R.A., W.A.A.: study design and literature search. T.A., S.A.A., S.A., A.S.M.A., F.A.A., S.K.A., A.K.A., H.T.A., K.S.A., R.A.A., S.A.A., A.M.A., S.A.A., T.A.A., M.S.A., A.M.M., S.A.A., A.A.A., R.A., N.F.: literature search and the data collection for the preparation of the tables and figures. A.A.A. and Z.R.: manuscript drafting. All authors have read and approved the final manuscript for publication.

Conflict of interest: Authors state no conflict of interest.

Data availability statement: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

References

[1] Hibbett DS, Binder M, Bischoff JF, Blackwell M, Cannon PF, Eriksson OE, et al. A higher-level phylogenetic classification of the Fungi. Mycol Res. 2007 May;111(5 Pt 5):509–47. doi: 10.1016/j.mycres.2007.03.004. Epub 2007 Mar 13. PMID: 17572334.

[2] Petrikkos G, Skiaa A, Lortholary O, Rollides E, Walsh Tj, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012 Feb;54(Suppl 1):S23–34. doi: 10.1093/cid/cir866. PMID: 22247442.

[3] Pasero D, Sanna S, Liperi C, Piredda D, Branca GP, Casadio L, et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection. 2021 Oct;49(5):1055–60. doi: 10.1007/s15010-020-01561-x. Epub 2020 Dec 17. PMID: 33331988; PMCID: PMC7745708.

[4] Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020 May 1;130(5):2620–9. doi: 10.1172/JCI137244. PMID: 32217835; PMCID: PMC7190990.

[5] Chakrabarti A, Singh R. Mucormycosis in India: unique features. Mycoses. 2014 Dec;57(Suppl 3):85–90. doi: 10.1111/myc.12243. Epub 2014 Sep 3. PMID: 25187095.

[6] Hoog GSde, Guarro J, Gene JFM. Atlas of Clinical Fungi. 3rd edn. Utrecht, Netherlands: Cen; 2009. https://www.clinicalfungi.org/ Last accessed March 29, 2022.

[7] Whittaker RH. New concepts of kingdoms or organisms. Evolutionary relations are better represented by new classifications than by the traditional two kingdoms. Science. 1969 Jan 10;163(3863):150–60. doi: 10.1126/science.163.3863.150. PMID: 5762760.

[8] Richardson M. The ecology of the zygomycetes and its impact on environmental exposure. Clin Microbiol Infect. 2009 Oct;15(Suppl 5):2–9. doi: 10.1111/j.1469-0691.2009.02972.x. PMID: 19754749.

[9] Mousavi B, Costa JM, Arré P, Guilhot J, Chermette R, Botterel F, et al. Occurrence and species distribution of pathogenic Mucorales in unselected soil samples from France. Med Mycol. 2018 Apr 1;56(3):315–21. doi: 10.1093/mmy/myx051. PMID: 28992337.

[10] Bloch KC, Myint T, Raymond-Guillen L, Hage CA, Davis TE, Wright PW, et al. Improvement in diagnosis of histoplasma meningitis by combined testing for histoplasma antigen and immunoglobulin g and immunoglobulin m anti-histoplasma
antibody in cerebrospinal fluid. Clin Infect Dis. 2018 Jan 6;66(1):89–94. doi: 10.1093/cid/cix706. PMID: 29020213; PMCID: PMC5850023.

[11] Malo J, Holbrook E, Zangeneh T, Strawter C, Oren E, Robey I, et al. Enhanced antibody detection and diagnosis of coccidioidomycosis with the miravista IgG and IgM detection enzyme immunoassay. J Clin Microbiol. 2017 Mar;55(3):893–901. doi: 10.1128/JCM.01880-16. Epub 2017 Jan 4. PMID: 28053216; PMCID: PMC5528457.

[12] Walther G, Wagner I, Kurzai O. Updates on the taxonomy of mucorales with an emphasis on clinically important taxa. J Fungi (Basel). 2019 Nov 14;5(4):106. doi: 10.3390/jof5040106. PMID: 31739583; PMCID: PMC6958464.

[13] Roden MM, Zaatoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005 Sep 1;41(5):634–93. doi: 10.1086/432579. Epub 2005 Jul 29. PMID: 16080086.

[14] Neofytos D, Horn D, Anaissie E, Olyaei A, Fishman J, Pfaller M, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009 Feb 1;48(3):265–73. doi: 10.1086/595846. Erratum in: Clin Infect Dis. 2009 Mar 1;48(5):690. PMID: 19115967.

[15] El Zein S, El-Cheikh J, El Zakhem A, Ibrahim D, Bazarbachi A, Kanj SS. Mucormycosis in hospitalized patients at a tertiary care center in Lebanon: a case series. Infection. 2018 Dec;46(6):811–21. doi: 10.1007/s11285-018-1195-4. Epub 2018 Aug 18. Erratum in: Infection 2018 Sep 1;46(9):1062. doi: 10.1007/s11285-018-1195-4. Epub 2019 Jan 9. PMID: 30121719.

[16] Hedayati MT, Taghzideh Armaki M, Yazdani Charati J, Hedayati N, Seyedmousavi S, Denning DW. Burden of fungal infections in Iran. J Infect Dev Ctries. 2018 Oct 31;12(10):910–8. doi: 10.3855/jidc.10476. PMID: 32004161.

[17] Zafar S, Prabhu A. Rhino-orbital-cerebral mucormycosis: recovery against the odds. Pract Neurol. 2017 Dec;17(6):485–8. doi: 10.1136/practneurol-2017-001671. Epub 2017 Aug 26. PMID: 28846400.

[18] Sakamoto H, Itanaga H, Sawayama Y, Taguchi J, Saijo T, Kuwatsuka S, et al. Primary oral mucormycosis due to rhizopus microsporus after allogeneic stem cell transplantation. Intern Med. 2018;57(17):2567–71. doi: 10.2169/internalmedicine.0474-17. Epub 2018 Sep 1. PMID: 30175728; PMCID: PMC6672532.

[19] Ghuman H, Voelz K. Innate and adaptive immunity to mucorales. J Fungi (Basel). 2017 Sep 5;3(3):48. doi: 10.3390/jof3030048. PMID: 29371565; PMCID: PMC5719554.

[20] Fung M, Schwartz BS, Doernberg SB, Langelier C, Lo M, Graff L, et al. Breakthrough invasive fungal infections on isavuconazole prophylaxis and treatment: What is happening in the real-world setting? Clin Infect Dis. 2018 Sep 14;67(7):1142–3. doi: 10.1093/cid/ciy260. PMID: 29617983; PMCID: PMC6629529.

[21] Rausch CR, DiPippo AJ, Bose P, Kontoyiannis DP. Breakthrough fungal infections in patients with leukemia receiving isavuconazole. Clin Infect Dis. 2018 Oct 30;67(10):1610–3. doi: 10.1093/cid/ciy406. PMID: 29771293; PMCID: PMC6454429.

[22] Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis. 2007 Apr 15;44(8):1089–90. doi: 10.1086/512817. Epub 2007 Mar 2. PMID: 17366455.

[23] Bavikar P, Mehta V. Rhino-orbital-cerebral mucormycosis: A fatal complication of uncontrolled diabetes mellitus. Cureus. 2017 Nov 15;9(11):e1841. doi: 10.7759/cureus.1841. PMID: 29348897; PMCID: PMC5768320.

[24] Binder U, Maurer E, Lass-Flohr C. Mucormycosis-from the pathogen to the disease. Clin Microbiol Infect. 2014 Jun;20(Suppl 6):60–6. doi: 10.1111/1469-0691.12566. Epub 2014 Feb 24. PMID: 24476169.

[25] Mousavi B, Botterel F, Costa JM, Arné P, Guillot J, Dannaoui E. Occurrence and species diversity of human-pathogenic Mucorales in commercial food-stuffs purchased in Paris area. Med Mycol. 2019 Aug 1;57(6):739–44. doi: 10.1093/medmyc/mmy121. PMID: 30428080.

[26] Bonifaz A, Stchigel AM, Guarro J, Guevara E, Pintos L, Sanchis M, et al. Primary cutaneous mucormycosis produced by the new species Apophysomyces mexicanus. J Clin Microbiol. 2014 Dec;52(12):4428–31. doi: 10.1128/JCM.02138-14. Epub 2014 Oct 8. PMID: 25297328; PMCID: PMC4313335.

[27] Skliada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, et al. European Confederation of Medical Mycology Working Group on Zygomycosis. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011 Dec;17(12):1859–67. doi: 10.1111/j.1469-0691.2010.03456.x. Epub 2011 Jul 1. PMID: 21199154.

[28] Al-Ajam MR, Bizri AR, Mokhbat J, Weeden J, Lukwic L. Mucormycosis in the Eastern Mediterranean: a seasonal disease. Epidemiol Infect. 2006 Apr;134(2):341–6. doi: 10.1017/S0950268805004930. PMID: 16490139; PMCID: PMC2870385.

[29] El-Herte RI, Baban TA, Kanj SS. Mucormycosis: a review on environmental fungal spores and seasonal variation of human disease. Adv Infect Dis. 2012;2:76–81. doi: 10.4236/aid.2012.23012.

[30] Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019 Mar 21;5(1):26. doi: 10.3390/jof5010026. PMID: 30901907; PMCID: PMC6462913.

[31] Chakrabarti A, Das A, Mandal J, Shivaprakash MR, George VK, Tarai B, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006 Jun;44(4):335–42. doi: 10.1080/1369378050046930. PMID: 16772227.

[32] Lanternier F, Dananou E, Moritz G, Elie C, Garcia-Hermoso D, Huerre M, et al. French Mycosis Study Group. A global analysis of mucormycosis in France: the RetroZygo Study (2005–2007). Clin Infect Dis. 2012 Feb;54(Suppl 1):S35–43. doi: 10.1093/cid/cir880. PMID: 22247443.

[33] Pagano L, Valentini CG, Postararo B, Girmenia C, Ossi C, Pan A, et al. Zygomycosis in Italy: a survey of FIMUA cases from the European Confederation of Medical Mycology (2006–2014). Cureus. 2017 Nov 13;9(11):e2322. doi: 10.7759/cureus.2322. PMID: 29225496.
[34] Patel A, Kaur H, Hess I, Michael JS, Savio J, Rudraramthy S, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020 Jul;26(7):944.e9–15. doi: 10.1016/j.cmi.2019.11.021. Epub 2019 Dec 4. PMID: 31811914.

[35] Cornely OA, Arika-Ankadi M, Damnouli E, Groll AH, Lagrou K, Chakrabarti A, et al. European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group; European Confederation of Medical Mycology; ESCMID and ECMC joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014 Apr;20(Suppl 3):i5–26. doi: 10.1111/1469-0691.12371. PMID: 24479848.

[36] Chakrabarti A, Chatterjee SS, Das A, Panda N, Shivaparakash MR, Kaur A, et al. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J. 2009 Nov;85(1009):573–81. doi: 10.1136/pgmj.2008.076463. PMID: 19892892.

[37] Prakash H, Ghosh AK, Rudraramthy SM, Singh P, Xess I, Savio J, et al. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol. 2019 Jun 1;57(4):395–402. doi: 10.1093/mmy/myy060. PMID: 30085158.

[38] Vaezi A, Moazeni M, Rahimi MT, de Hoog S, Badali H. Mucormycosis in Iran: a systematic review. Mycoses. 2016 Jul;59(7):402–15. doi: 10.1111/myc.12474. Epub 2016 Feb 15. PMID: 26906121.

[39] Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases. Med Mycol. 2018 Jan 1;56(1):29–43. doi: 10.1093/mmy/mxy017. PMID: 28431008.

[40] Stemler J, Hamed K, Salmontón-García J, Rezaei-Matehkolaei A, Gräfe SK, Sal E, et al. Mucormycosis in the Middle East and North Africa: Analysis of the FungiScope® registry and cases from the literature. Mycoses. 2020 Oct;63(10):1060–8. doi: 10.1111/myc.13123. Epub 2020 Aug 29. PMID: 32485012.

[41] Skiada A, Petrikkos G. Cutaneous zygomycosis. Clin Microbiol Infect. 2009 Oct;15(Suppl 5):37–45. doi: 10.1111/j.1469-0691.2009.02999.x. PMID: 19754760.

[42] Koussiappi E, Poryfriedis I, Karagiannis C, Adamide T, Georgiou A. Pulmonary Mucormycosis (Zygomycosis) presenting as an infective exacerbation of chronic obstructive pulmonary disease. Eur J Case Rep Intern Med. 2018 Dec 27;5(12):000995. doi: 10.12890/2018_000995. PMID: 30756000; PMCID: PMC6346968.

[43] Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019 Jan;25(1):26–34. doi: 10.1016/j.cmi.2018.07.011. Epub 2018 Jul 21. PMID: 30036666.

[44] Skiada A, Pavlou I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: An update. J Fungi (Basel). 2020 Nov 2;6(4):265. doi: 10.3390/jof6040265. PMID: 33147877; PMCID: PMC7711598.

[45] Moura DTH, Proença IM, McCarty TR, Sages VMT, Ribeiro IB, Oliveira GHP, et al. Gastrointestinal manifestations and associated health outcomes of COVID-19: A brazilian experience from the largest South American public hospital. Clin (Sao Paulo). 2020 Oct 26;75:e2271. doi: 10.6061/clinics/2020/e2271. PMID: 31963632; PMCID: PMC7601063.

[46] Garg M, Prabhabkar N, Muthu V, Farookh S, Kaur H, Suri V, et al. Findings of COVID-19-associated pulmonary mucormycosis: a case series and literature review. Radiology. 2022 Jan;302(1):214–7. doi: 10.1148/radiol.2021211583. Epub 2021 Aug 31 PMID: 34463553; PMCID: PMC8717667.

[47] Selarka L, Sharma S, Saini D, Sharma S, Batra A, Waghmare VT, et al. Mucormycosis and COVID-19: An epidemic within a pandemic in India. Mycoses. 2021 Oct;64(10):1253–60. doi: 10.1111/myc.13353.

[48] Kamrul-Hasan AB, Selim S. Mucormycosis, the deadly new worry to COVID-19 pandemic. Mymensin Medical J. 2021 Jul 1;30(3):874–80. PMID: 34226483.

[49] Legouge C, Caillot D, Chrétien ML, Lafon I, Ferrant E, Audia S, et al. The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? Clin Infect Dis. 2014 Mar;58(5):672–8. doi: 10.1093/cid/cit929. Epub 2013 Dec 18. PMID: 24352351.

[50] Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med. 2001 Mar;125(3):375–8. doi: 10.1085/125-0375-0375-HFOZ. PMID: 11231486.

[51] Lass-Fliör C. Zygomycosis: conventional laboratory diagnosis. Clin Microbiol Infect. 2009 Oct;15(Suppl 5):50–5. doi: 10.1111/j.1469-0691.2009.02999.x. PMID: 19754760.

[52] Lass-Fliör C, Resch G, Nachbaur D, Mayr A, Gastl G, Auberer J, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis. 2007 Oct 1;45(7):e101–4. doi: 10.1086/521245. Epub 2007 Aug 20. PMID: 17806041.

[53] Suganya R, Malathi N, Karthikeyan V. Mucormycosis: a brief review. J Pure Appl Microbiol. 2019;13:161–5. doi: 10.22207/jpam.13.1.16.

[54] Walsh TJ, Gameletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012 Feb;54(Suppl 1):S55–60. doi: 10.1093/cid/cir868. PMID: 22247446.

[55] Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005 Jul 1;41(1):60–6. doi: 10.1086/430710. Epub 2005 May 24. PMID: 15937764.

[56] Patel NR, Patel PA. A case report of mucormycosis with palatal ulcer: A rare clinical dilemma. J Coll Physicians Surg Pak. 2018 Sep;28(9):721–3. doi: 10.29271/jcpps.2018.09.721. PMID: 30158044.

[57] Skiada A, Lanterner F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, et al. European Conference on Infections in Leukemia. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2013 Apr;98(4):492–504. doi: 10.3324/haematol.2012.065110. Epub 2012 Sep 14. PMID: 22983580; PMCID: PMC3659979.
Son HJ, Song JS, Choi S, Jung J, Kim MJ, Chong YP, et al. A comparison of histomorphologic diagnosis of aspergillosis and mucormycosis. Clin Infect Dis. 2015 Dec 1;61(11):1664–70. doi: 10.1093/cid/civ660. Epub 2015 Aug 3. PMID: 26240202.

Son HJ, Song JS, Choi S, Jung J, Kim MJ, Chong YP, et al. A comparison of histomorphologic diagnosis with culture- and immunohistochemistry-based diagnosis of invasive aspergillosis and mucormycosis. Infect Dis (Lond). 2020 Apr;52(4):279–83. doi: 10.1080/23744235.2020.1716063. Epub 2020 Jan 23. PMID: 31973617.

Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Rolildes E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018 Apr 1;56(suppl_1):93–101. doi: 10.1093/amy/myx101. PMID: 29538730; PMCID: PMC6255132.

Hsiao CR, Huang L, Bouchara JP, Barton R, Li HC, Chang TC. Identification of medically important molds by an oligonucleotide array. J Clin Microbiol. 2005 Aug;43(8):3760–8. doi: 10.1128/JCM.43.8.3760-3768.2005. PMID: 16081907; PMCID: PMC1239232.

Nagao K, Ota T, Tanikawa A, Takae Y, Mori T, Udagawa S, et al. Genetic identification and detection of human pathogenic Rhizopus species, a major mucormycosis agent, by multiplex PCR based on internal transcribed spacer region of rRNA gene. J Dermatol Sci. 2005 Jul;39(1):23–31. doi: 10.1016/j.jdermsci.2005.01.010. Epub 2005 Feb 25. PMID: 15978416.

Larché J, Machouart M, Burton K, Collomb J, Biava MF, Gérard A, et al. Diagnosis of cutaneous mucormycosis due to Rhizopus microsporus by an innovative PCR restriction fragment-length polymorphism method. Clin Infect Dis. 2005 Nov 1;41(9):1362–5. doi: 10.1086/497078. PMID: 16206119.

Machouart M, Larché J, Burton K, Collomb J, Maurer P, Cintrat A, et al. Genetic identification of the main opportunistic Mucorales by PCR restriction fragment length polymorphism. J Clin Microbiol. 2006 Mar;44(3):805–10. doi: 10.1128/JCM.44.3.805-810.2006. PMID: 16517858; PMCID: PMC1393117.

Nyland I, Papp T, Csernetics A, Krizsán K, Nagy E, Vágvölgyi C. High-affinity iron permease (FTR1) gene sequence-based molecular identification of clinically important Zygomyces. Clin Microbiol Infect. 2008 Apr;14(4):393–7. doi: 10.1111/j.1469-0691.2007.01932.x. Epub 2008 Jan 11. PMID: 18190575.

Springer J, Lackner M, Ensinger C, Rissligger B, Morton CO, Nachbaur D, et al. Clinical evaluation of a Mucorales-specific real-time PCR assay in tissue and serum samples. J Med Microbiol. 2016 Dec;65(12):1414–21. doi: 10.1099/jmm.0.003375. Epub 2016 Oct 24. PMID: 27902424.

Wong G, Wong I, Chan K, Hsieh Y, Wong S. A rapid and low-cost pcr thermal cycler for low resource settings. PLoS One. 2015 Jun 6;10(7):e0131701. doi: 10.1371/journal.pone.0131701. PMID: 26146999; PMCID: PMC4492969.

Gholinejad-Ghadi N, Shokohi T, Selfi Z, Aghili SR, Rolildes E, Nikkhah M, et al. Identification of Mucorales in patients with proven invasive mucormycosis by polymerase chain reaction in tissue samples. Mycoses. 2018 Dec;61(12):909–15. doi: 10.1111/myc.12837. Epub 2018 Aug 28. PMID: 30091261.

Zaman K, Rudramurthy SM, Das A, Panda N, Honnavar P, Kaur H, et al. Molecular diagnosis of rhino-orbito-cerebral mucormycosis from fresh tissue samples. J Med Microbiol. 2017 Aug;66(8):1124–9. doi: 10.1099/jmm.0.000560. Epub 2017 Aug 9. PMID: 28792370.

Alano A, Garcia-Herrero D, Mercier-Delarue S, Lanterner F, Gits-Muselli M, Menotti J, et al. French Mycosis Study Group Molecular identification of Mucorales in human tissues: contribution of PCR electrospray-ionization mass spectrometry. Clin Microbiol Infect. 2015 Jun;21(6):S94.e1–S94.e5. doi: 10.1016/j.cmi.2015.01.017. Epub 2015 Jan 28. PMID: 25726039.

Lengerova M, Racil Z, Hrncirova K, Kocmanova I, Volfova P, Lengerova M, et al. Langeron M, Racil Z, Hrncirova K, Kocmanova I, Volfova P, Lengerova M, et al. Rapid detection and identification of mucormycetes in bronchoalveolar lavage samples from immunocompromised patients with pulmonary infiltrates by use of high-resolution melt analysis. J Clin Microbiol. 2014 Aug;52(8):2824–8. doi: 10.1128/JCM.00637-14. Epub 2014 May 21. PMID: 24805354; PMCID: PMC4136189.

Dannanou E. Molecular tools for identification of Zygomyces and the diagnosis of zygomycosis. Clin Microbiol Infect. 2009 Oct;15(Suppl 5):66–70. doi: 10.1111/j.1469-0691.2009.02983.x. PMID: 19754761.

García-Herrero D. Diagnostic microbiologique des mucoroses [Laboratory diagnosis of mucormycosis]. Med Sci (Paris). 2013;29(Spec No 1):13–8. doi: 10.1051/medsci/201329s104.

Dawdell SS, Kontoyiannis DP. Recent advances in the molecular diagnosis of mucormycosis. Expert Rev Mol Diagn. 2018 Oct;18(10):845–54. doi: 10.1080/14737159.2018.1522250. Epub 2018 Sep 19. PMID: 30203997.

Baldin C, Soliman SSM, Jeon HH, Alkazzaraj S, Gebremariam T, Gu Y, et al. PCR-Based approach targeting mucorales-specific gene family for diagnosis of mucormycosis. J Clin Microbiol. 2018 Sep 25;56(10):e00746-18. doi: 10.1128/JCM.00746-18. PMID: 30068535; PMCID: PMC6156309.

Lackner M, Caramalho R, Lass-Förl C. Laboratory diagnosis of mucormycosis: current status and future perspectives. Future Microbiol. 2014;9(5):683–95. doi: 10.2217/fmb.14.23. PMID: 24957094.

Legrand M, Gits-Muselli M, Boutin L, Garcia-Herrero D, Maurel V, Soussi S, et al. Detection of circulating DNA in critically Ill burn patients: Preliminary report of a screening strategy for early diagnosis and treatment. Clin Infect Dis. 2016 Nov 15;63(10):1312–7. doi: 10.1093/cid/ciw563. Epub 2016 Aug 17 PMID: 27535951.

Millon L, Larosa F, Lepiller Q, Legrand F, Rocchi S, Daguinadu E, et al. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. Clin Infect
Lopes JO, Pereira DV, Streher LA, Fenalte AA, Alves SH, Guinea J, Escribano P, Vena A, Muñoz P, Martínez-Jiménez MDC, Padilla B, et al. Correction: Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates. PLoS One. 2020 Feb 12;15(2):e0229347. doi: 10.1371/journal.pone.0229347. Erratum for: PLoS One. 2017 Jun 7;12(6):e0179136. PMID: 32049980; PMCID: PMC7015364.

Ino K, Nakase K, Nakamura A, Nakamori Y, Sugawara Y, Miyazaki K, et al. Management of pulmonary mucormycosis based on a polymerase chain reaction (PCR) diagnosis in patients with hematologic malignancies: a report of four cases. Intern Med. 2017;56(6):707–11. doi: 10.2169/internalmedicine.56.7647. Epub 2017 Mar 17. PMID: 28321075; PMCID: PMC5410485.

Millon L, Herbrecht R, Grenouillet F, Morio F, Alanio V, Letscher-Bru V, et al. French Mycosis Study Group Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). Clin Microbiol Infect. 2016 Sep;22(9):810.e1–8. doi: 10.1016/j.cmi.2015.12.006. Epub 2015 Dec 17. PMID: 26706615.

Kasai M, Harrington SM, Francesconi A, Petrattis V, Petrattiene R, Beveridge MG, et al. Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol. 2008 Nov;46(11):3690–702. doi: 10.1128/JCM.00917-08. Epub 2008 Sep 24. PMID: 18845827; PMCID: PMC2576616.

Goodman NL, Rinaldi MG. Agents of mucormycosis. In: Balows A, Hausler WJ, Hermann KL, Isenberg HD, Shadomy HJ, editors. Manual of clinical microbiology. 5th edn. Washington, DC: ASM Press; 1991. https://www.jstor.org/stable/41353455.

Lopes JO, Pereira DV, Streher LA, Fenalte AA, Alves SH, Benevenga JP. Cutaneous zygomycosis caused by Absidia corymbifera in a leukemic patient. Mycopathologia. 1995 May;130(2):89–92. doi: 10.1007/BF01034555. PMID: 7566062.

Stas KJ, Louwagie PG, Van Damme BJ, Coosemans W, Waer M, Vanrengem YF. Isolated zygomycosis in a bought living unrelated kidney transplant. Transpl Int. 1996;9(6):600–2. doi: 10.1007/BF03355633. PMID: 8914243.

Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102166. doi: 10.1016/j.dsx.2021.05.019. Epub 2021 May 21. PMID: 34192610; PMCID: PMC8137376.

Dallalzadeh LO, Ozzello DJ, Liu CY, Kikkawa DO, Korn BS. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. Orbit. 2021 Mar 23;–4. doi: 10.1080/01676830.2021.1903044. Epub ahead of print. PMID: 33752571.

Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021 Apr;42:264.e5–8. doi: 10.1016/j.ajem.2020.09.032. Epub 2020 Sep 16. PMID: 32972795; PMCID: PMC7493738.

Placik DA, Taylor WL, Wnuk NM. Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. Radiol Case Rep. 2020 Nov;15(11):2378–81. doi: 10.1016/j.radcr.2020.09.026. Epub 2020 Sep 18. PMID: 32983308; PMCID: PMC7500914.

Mekonnen ZK, Ashraf DC, Jankowski T, Grob SR, Vagefi MR, Kersten RC, et al. Acute invasive rhino-orbital mucormycosis in a patient with covid-19-associated acute respiratory distress syndrome. Ophthalmic Plast Reconstr Surg. 2021 Mar-Apr 01;37(2):e40–80. doi: 10.1097/IOP.0000000000001889. PMID: 33229953; PMCID: PMC7927902.

Alekseyev K, Didenko L, Chaudhry B. Rhinocerebral mucormycosis and COVID-19 pneumonia. J Med Cases. 2021 Mar;12(3):85–9. doi: 10.14740/jmc3637. Epub 2021 Jan 19. PMID: 33984095; PMCID: PMC8040444.

Johnson AK, Ghazarian Z, Cendrowski KD, Persichino JG. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med Mycol Case Rep. 2021 Jun;32:64–7. doi: 10.1016/j.mcr.2021.03.006. Epub 2021 Apr 7. PMID: 33842203; PMCID: PMC8025540.

Kanwar A, Jordan A, Olewiler S, Webberg K, Cortes M, Jackson BR. A fatal case of Rhizopus azigusporus pneumonia following COVID-19. J Fungi (Basel). 2021 Feb 28;7(3):174. doi: 10.3390/jof7030174. PMID: 33670842; PMCID: PMC7997212.

Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient – Case report and review of literature. J Mycol Med. 2021 Jun;31(2):10125. doi: 10.1016/j.jmycmd.2021.10125. Epub 2021 Apr 2. PMID: 33857916; PMCID: PMC8017948.

Monte Junior ESD, Santos MEID, Ribeiro IB, Luz GO, Baba ER, Hirsch BS, et al. Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: a case report. Clin Endosc. 2020 Nov;53(6):746–9. doi: 10.5946/ce.2020.180. Epub 2020 Nov 19. PMID: 33207116; PMCID: PMC7719411.

Revannavar SM, Supriya PS, Samaga L, Vineeth V. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep. 2021 Apr 27;14(4):e241663. doi: 10.1136/bcr-2021-241663. PMID: 33906877; PMCID: PMC8088249.

Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a Viral Land: A Tale of Two Pathogens. Indian J Ophthalmol. 2021 Feb;69(2):244–52. doi: 10.4103/ijo.IJO_3774_20. PMID: 33463566; PMCID: PMC7933891.

Sarkar S, Gokhale T, Choudhry SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol. 2021 Apr;69(4):1002–4. doi: 10.4103/ijo.IJO_3763_20. Erratum in: Indian J Ophthalmol. 2021 Jul;69(7):1978. PMID: 33727483; PMCID: PMC8012924.
[102] Mishra N, Mutya VSS, Thomas A, Rai G, Reddy B, Mohanan AA, et al. A case series of invasive mucormycosis in patients with COVID-19 infection. Int J Otorhinolaryngol Head Neck Surg. 2021;7(5):867–70. doi: 10.18203/issn.2454-5929.ijohnhs20211583.

[103] Satish D, Joy D, Ross A. Balasubramanyam: Mucormycosis co-infection associated with global COVID-19: a case series from India. Int J Otorhinolaryngol Head Neck Surg. 2021;7(5):815–20. doi: 10.18203/issn.2454-5929.ijohnhs20211574.

[104] Moorthy A, Galkward R, Krishna S, Hegde R, Tripathi KK, Kale PG, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids—an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021 Sep;20(3):418–25. doi: 10.1007/s12663-021-01532-1. Epub 2021 Mar 6. PMID: 33716414; PMCID: PMC7936599.

[105] Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021 May;135(5):442–7. doi: 10.1017/S0022215121009992. Epub 2021 Apr 8. PMID: 33827722; PMCID: PMC8060455.

[106] Hanley B, Naresh KN, Roufesse C, Nicholson AG, Weir J, Cooke GS, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020 Oct;1(6):e245–53. doi: 10.1016/S2666-5247(20)30115-4. Epub 2020 Aug 20. PMID: 32844161; PMCID: PMC7440861.

[107] Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020 Sep 30;12(9):e10726. doi: 10.7759/cureus.10726. PMID: 33145132; PMCID: PMC7599039.

[108] Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia. 2021 May;186(2):289–98. doi: 10.1007/s11046-021-00528-2. Epub 2021 Feb 5. PMID: 35344266; PMCID: PMC8762973.

[109] Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: A case report. Int J Curr Surg Case Rep. 2021 May;82:105957. doi: 10.1016/j.jiscrcase.2021.105957. Epub 2021 May 4. PMID: 33964720; PMCID: PMC8903005.

[110] Saldanha M, Reddy R, Vincent MJ. Title of the Article: Paranasal Mucormycosis In COVID-19 Patient. Indian J Otolaryngol Head Neck Surg. 2021 Apr;22:1–4. doi: 10.1007/s12070-021-02574-0. Epub ahead of print. PMID: 33903850; PMCID: PMC8060684.

[111] Bellanger AP, Naveilou JC, Lepiller Q, Brion A, Brunel AS, Millon L, et al. Mixed mold infection with Aspergillus fumigatus and Rhizopus microsorus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. Infect Dis Now. 2021 Oct;51(7):633–5. doi: 10.1016/j.idnow.2021.01.010. Epub 2021 Jan 27. PMID: 33527098; PMCID: PMC7839422.

[112] Karimi-Galougahi M, Arastou S, Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol. 2021 Jun;11(6):1029–30. doi: 10.1002/air.22785. Epub 2021 Mar 13. PMID: 33713565; PMCID: PMC8250489.

[113] Veisi A, Bagheri A, Esghahi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. Eur J Ophthalmol. 2021 Apr 10;11206721211009450. doi: 10.1177/11206721211009450. Epub ahead of print. PMID: 33843287.

[114] Sargin F, Akbulut M, Karaduman S, Sungurtekin H. Severe rhinocerebral mucormycosis case developed After COVID 19. J Bacteriol Parasitol. 2021;12:386–90.

[115] Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrrez L. A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus. 2021 Feb 5;13(2):e13163. doi: 10.7759/cureus.13163. PMID: 33575155; PMCID: PMC7870113.

[116] Zurl C, Hoenigl M, Schulz E, Hatzl S, Gorkiewicz K, Krause R, et al. Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy. J Fungi (Basel). 2021 Jan 27;7(2):88. doi: 10.3390/jof7020088. PMID: 33518375; PMCID: PMC7912223.

[117] Pauli MA, Pereira LM, Monteiro ML, de Camargo AR, Rabelo GD. Painful palatal lesion in a patient with COVID-19. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Jun;131(6):620–5. doi: 10.1016/j.oooo.2021.03.010.

[118] Rao R, Shetty AP, Nagesh CP. Orbital infarction syndrome secondary to rhino-orbital mucormycosis in a case of COVID-19: Clinico-radiological features. Indian J Ophthalmol. 2021 Jun;69(6):1627–30. doi: 10.4103/jioi.IJO_1053_21.

[119] Ravani SA, Agrawal GA, Leuva PA, Modi PH, Amin KD. Rise of the phoenix: Mucormycosis in COVID-19 times. Indian J Ophthalmol. 2021 Jun;69(6):1563–8. doi: 10.4103/jioi.IJO_310_21.

[120] Pakdel F, Ahmadihikia K, Salehi M, Tabari A, Jafari R, Mehrparvar G, et al. Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran. Mycoses. 2021 Oct;64(10):1238–52. doi: 10.1111/myc.13334.

[121] Singh RP, Gupta N, Kaur T, Gupta A. Rare case of gastrointestinal mucormycosis with colonic perforation in an immunocompetent patient with COVID-19. BJM Case Rep. 2021 Jul 2;14(7):e244096. doi: 10.1136/bcr-2021-244096.

[122] Arjun R, Felix V, Niyas VKM, Kumar MAS, Krishnan RB, Mohan V, et al. COVID-19-associated rhino-orbital mucormycosis: a single-centre experience of 10 cases. QJM. 2022 Jan;115(1):831–4. doi: 10.1093/qjmed/hcab176.

[123] Saidha PK, Kapoor S, Das P, Gupta A, Kakkar V, Kumar A, et al. Mucormycosis of paranasal sinuses of odontogenic origin post COVID-19 infection: a case series. Indian J Otolaryngol Head Neck Surg. 2021 Jun 17;1:5. doi: 10.1007/s12070-021-02638-1.

[124] Jain M, Tyagi R, Tyagi R, Jain G. Post-COVID-19 GASTROINTESTINAL INVASIVE MUCORMycosis. Indian J Surg. 2021 Jun 22;84(1–3): doi: 10.1007/s12262-021-03007-6.

[125] Arana C, Cuevas Ramirez RE, Xipell M, Casals J, Moreno A, Herrera S, et al. Mucormycosis associated with COVID-19 in two kidney transplant patients. Transpl Infect Dis. 2021 Aug;23(4):e13652. doi: 10.1111/tid.13652.

[126] Baskar HC, Chandran A, Reddy CS, Singh S. Rhino-orbital mucormycosis in a COVID-19 patient. BMJ Case Rep. 2021 Jun 24;14(6):e244232. doi: 10.1136/bcr-2021-244232.
patients - Is ferritin the product of inflammation or a pathogenic mediator? Clin Chim Acta. 2020 Oct;509:249–51. doi: 10.1016/j.cca.2020.06.033.

[156] Sonnweber T, Boehm A, Sahanic S, Pizzini A, Aichner M, Sonnweber B, et al. Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients’ performance: a prospective observational cohort study. Respir Res. 2020 Oct 21;21(1):276. doi: 10.1186/s12931-020-01546-2.

[157] Kieliszek M, Lipinski B. Selenium supplementation in the prevention of coronavirus infections (COVID-19). Med Hypotheses. 2020 Oct;143:109878. doi: 10.1016/j.mehy.2020.109878.